FORM	4
------	---

Check this box if no	
longer subject to Section	
16. Form 4 or Form 5	
obligations may	Б
continue. See Instruction	г
1(b).	

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Intons may nue. See Instruction Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)										
1. Name and Address of Reporting Person Arsenault Kaitlyn Melanie	2. Issuer Name and Ticker or Trading Symbol Skye Bioscience, Inc. [SKYE]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner			
(Last) (First) 11250 EL CAMINO REAL, SUIT BIOSCIENCE, INC.		3. Date of Earliest Transaction (Month/Day/Year) 12/14/2021						X_Officer (give title below)Other (specify below) Chief Financial Officer		
(Street) SAN DIEGO, CA 92130		4. If Amendment, Date Original Filed(Month/Day/Year)						6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting Person Form filed by More than One Reporting Person		
(City) (State)	(Zip)	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned								
1. Title of Security 2. Transaction (Instr. 3) Date (Month/Day/Yea)		Execution Date, if any	(Instr. 8) (Instr. 3, 4 and 5)			of (D)	ed (A)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s)	7. Nature of Indirect Beneficial	
		(Month/Day/Year)	Code	v	Amount	(A) or (D)	Price	(Instr. 3 and 4)	Direct (D) or Indirect (I) (Instr. 4)	Ownership (Instr. 4)
Common Stock	12/14/2021		А		1,000,000 (<u>1</u>)	А	(2)	1,000,000	D	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in SEC 1474 (9-02) this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

	(e.g., puts, caus, warrants, options, convertible securities)														
1. Title of	2.	3. Transaction	3A. Deemed	4.		5. Number of	f	6. Date Exer	cisable and	7. Title and	Amount of	8. Price of	9. Number of	10.	11. Nature
Derivative	Conversion	Date	Execution Date, if	Transac	tion	Derivative		Expiration Date		Underlying Securities		Derivative	Derivative	Ownership	of Indirect
Security	or Exercise	(Month/Day/Year)	any	Code		Securities		(Month/Day/Year)		(Instr. 3 and 4)		Security	Securities	Form of	Beneficial
(Instr. 3)	Price of		(Month/Day/Year)	(Instr. 8)	Acquired (A)) or					(Instr. 5)	Beneficially	Derivative	Ownership
	Derivative					Disposed of (Security:	(Instr. 4)
	Security					(Instr. 3, 4, a	nd						0	Direct (D)	
						5)						· · · · · · · · · · · · · · · · · · ·		or Indirect	
								Date	Expiration		Amount or		Transaction(s)	< / .	
								Exercisable		Title	Number of		(Instr. 4)	(Instr. 4)	
				Code	V	(A)	(D)	Excleisable	Date		Shares				
Stock															
Option										Common					
	\$ 0.058	12/14/2021		Α		1,770,000		<u>(3)</u>	12/14/2031	Stock	1,770,000.00	\$ 0	1,770,000	D	
(Right										SLOCK					
to Buy)															

Reporting Owners

	Relationships						
Reporting Owner Name / Address	Director	10% Owner	Officer	Other			
Arsenault Kaitlyn Melanie 11250 EL CAMINO REAL, SUITE 100 C/O SKYE BIOSCIENCE, INC. SAN DIEGO, CA 92130			Chief Financial Officer				

Signatures

/s/ Kaitlyn Arsenault	12/16/2021
Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Represents a restricted stock unit ("RSU") award that vests in three equal annual installments commencing on the first anniversary of the grant date. Upon a change in control of the Issuer, all of the RSUs will vest in full.
- (2) Each RSU represents a contingent right to receive one share of the Issuer's common stock.
- (3) The option vests 25% on the one year anniversary of the grant date and 1/48th monthly thereafter. Upon a change in control of the Issuer, 100% of the options will become fully vested.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.